Volume 5, Issue 4, December 2020, Page: 78-81
Pathological and Clinical Characteristics of Triple Negative Breast Cancer and Disease Relapse
Duaa Knaj, Department of Oncology, Faculty of Medicine, Tishreen University, Lattakia, Syria
Michael Georgeos, Oncology Department, Oncology Center, Tishreen University Hospital, Lattakia, Syria
Received: Aug. 29, 2020;       Accepted: Sep. 14, 2020;       Published: Nov. 19, 2020
DOI: 10.11648/j.ijcocr.20200504.11      View  23      Downloads  16
Background: Breast cancer is the most common cancer and an important cause of death in women. It has psychological and social repercussions in patients. Objective: We aimed to assess triple negative breast cancer characteristics, patterns and time of disease relapse. Patients and methods: We reviewed the clinical files and pathology reports of 100 patients who had primary triple-negative breast cancer between 2013 -2017 at the oncology center, Tishreen University Hospital in Lattakia, Syria. We collected the information about (age at diagnosis, histological subtype of tumor, histological grade, tumor size, tumor stage, lymph node status), which was taken at the time of diagnosis. We used SPSS in this research, and Chi-square test was used to compare variables. Results: We found that most of patients (85%) were 40 years of age and older when diagnosed with breast cancer. The most common histological subtype was invasive ductal carcinoma IDC (84%). Regarding the size of the primary tumor, the majority (72%) were T2. According to lymph node status at diagnosis, 41 patients (41%) were N0, (33%) of total were N1. We found grade 2 in 52%, followed by grade3 (41%). For the tumor clinical stage, it was according to AJCC 7th edition, stage II (63%) and stage III in (30%). We found that 32 patients had a recurrence (32%) while (68%) had no recurrence during the follow-up period. As for the development of recurrence, (40.6%) had visceral recurrence; the most pattern was hepatic (61.5%) then pulmonary (38.5%). Recurrence occurred in (22 of 32) patients during the first 2 years (68.7%). We found a significant association between lymph node status and recurrence in patients with TNBC (P=0.004) Conclusion: T and N were important predictive factors for relapse in patients with triple-negative breast cancer, which tends to recur often during the first two years of diagnosis with distant metastases as well as localized recurrence.
Triple Negative Breast Cancer, Characteristics, Relapse
To cite this article
Duaa Knaj, Michael Georgeos, Pathological and Clinical Characteristics of Triple Negative Breast Cancer and Disease Relapse, International Journal of Clinical Oncology and Cancer Research. Vol. 5, No. 4, 2020, pp. 78-81. doi: 10.11648/j.ijcocr.20200504.11
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Canadian Cancer Society’s Advisory Committee on Cance Statistics. Canadian Cancer Statistics 2017. Toronto, ON: Canada Cancer Society; 2017.
Schmadeka R, Harmon BE, Singh M. Triple-negative breast carcinoma: current and emerging concepts. Am J Clin Pathol 2014; 141: 462–77.
Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple- negative breast cancers: a systematic review and metaanalysis. Breast Cancer Res Treat 2013; 137: 307–14.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13: 4429–34.
Elston CW, Ellis JO: Pathological prognostic factors in breast cancer. 1. The value of histological grade 1n breast cancer: Experience from a long study with long-term follow –up. Histopathology 1991, 19: 40410.
Amin MB, Edge FL, Edge SB, et al. The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017; 67: 93-99.
T. Tarver, Cancer facts & figures 2012. American cancer society (ACS), J. Consum. Health Internet 16 (2012) 366e367.
Clin Cancer Res 2007; 4429 13 (15) August 1, 2007.
Urru et al. BMC Cancer (2018) 18: 56. DOI 10.1186/s12885-017-3969-y.
Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012; 118: 5463–72.
Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010; 12: 207.
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363: 1938–48.
National Comprehensive Cancer Network. Breast Cancer (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed August 1, 2019.
Brierley JD, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours. 8th. Oxford; UK: Wiley Blackwell: 2017.
Browse journals by subject